<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397670</url>
  </required_header>
  <id_info>
    <org_study_id>CCN 003OL</org_study_id>
    <nct_id>NCT00397670</nct_id>
  </id_info>
  <brief_title>Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm</brief_title>
  <official_title>A Multicenter Open-Label Study of the Safety and Contraceptive Efficacy of BufferGel® Spermicide Used With Diaphragm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReProtect Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ReProtect Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and contraceptive effectiveness of BufferGel&#xD;
      used with a contraceptive diaphragm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive efficacy (pregnancy rate) at six months (183 days).</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: BufferGel® with diaphragm</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be healthy women, who are sexually active, at risk for pregnancy and desiring&#xD;
             contraception&#xD;
&#xD;
          -  be within the age range of 18 through 40 years inclusive&#xD;
&#xD;
          -  be at low-risk for human immunodeficiency virus (HIV) or sexually transmitted disease&#xD;
             (STD) infection, currently have (≥4 months) a single sexual partner who is also at&#xD;
             low-risk for HIV or STD infection and expect to have the same partner for the duration&#xD;
             of the study&#xD;
&#xD;
          -  have a negative urine pregnancy test at the admission visit&#xD;
&#xD;
          -  have normal cyclic menses with a usual length of 24 to 35 days over the last 2 months&#xD;
&#xD;
          -  have a documented history of at least one spontaneous, normal menstrual cycle (two&#xD;
             menses) since delivery, abortion, or after discontinuing hormonal&#xD;
             contraception/hormonal therapy&#xD;
&#xD;
          -  be willing to accept a risk of pregnancy&#xD;
&#xD;
          -  be willing to engage in at least 4 acts of heterosexual vaginal intercourse per cycle&#xD;
             for a period of approximately seven months&#xD;
&#xD;
          -  be willing to be randomized to either study treatment as applicable&#xD;
&#xD;
          -  be willing to be fitted with a diaphragm and use the diaphragm with test product&#xD;
             during all acts of heterosexual vaginal intercourse for the duration of the study&#xD;
&#xD;
          -  be willing to only use the test product with diaphragm as the primary method of&#xD;
             contraception over the course of the study [with the exception of emergency&#xD;
             contraception pills (ECPs), when indicated]&#xD;
&#xD;
          -  be capable of using the product and diaphragm properly and agree to observe all study&#xD;
             directions and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have a history of allergy or sensitivity to spermicides, products containing N-9,&#xD;
             and/or products containing latex&#xD;
&#xD;
          -  have a history of toxic shock syndrome&#xD;
&#xD;
          -  have had two or more UTIs in the past year or currently have a suspected or diagnosed&#xD;
             UTI or vaginitis by dipstick urinalysis or wet mount, unless treated and proof of cure&#xD;
             is documented&#xD;
&#xD;
          -  be pregnant, have a suspected pregnancy or desire to become pregnant during the course&#xD;
             of the study&#xD;
&#xD;
          -  have a history of infertility or conditions which may lead to infertility&#xD;
&#xD;
          -  have contraindications to pregnancy (medical condition) or chronic use of class D or X&#xD;
             medications&#xD;
&#xD;
          -  have been hospitalized for pelvic inflammatory disease without a subsequent&#xD;
             intrauterine pregnancy&#xD;
&#xD;
          -  have had more than one sexual partner in the past 4 months&#xD;
&#xD;
          -  have shared injection drug needles within the past 6 months&#xD;
&#xD;
          -  have, or suspected to have, HIV infection&#xD;
&#xD;
          -  have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence&#xD;
             (initial episode) within the 3 months prior to screening, or have clinical evidence of&#xD;
             HSV on exam&#xD;
&#xD;
          -  have been diagnosed with any other STDs (including trichomonas) in the 6 months prior&#xD;
             to the screening visit&#xD;
&#xD;
          -  be lactating or breastfeeding have had a Depo-Provera injection in the 10 months&#xD;
             prior to screening&#xD;
&#xD;
          -  have a vaginal or cervical abnormality that would interfere with the proper placement&#xD;
             and retention of test product and diaphragm&#xD;
&#xD;
        In addition, in order to be eligible to participate in the trial, potential subjects must&#xD;
        state that, to her best knowledge, her sexual partner meets the following criteria:&#xD;
&#xD;
          -  is not infertile&#xD;
&#xD;
          -  has not been treated for Chlamydia trachomatis or N. gonorrhoeae in the past 6 months&#xD;
&#xD;
          -  has not been previously diagnosed with, or suspected to have, HIV infection&#xD;
&#xD;
          -  has not had more than one sexual partner in the past 4 months&#xD;
&#xD;
          -  has not engaged in homosexual intercourse in the past 10 years&#xD;
&#xD;
          -  has not shared injection drug needles in the past 10 years&#xD;
&#xD;
          -  has no history of allergy or sensitivity to spermicides or products containing N-9&#xD;
&#xD;
          -  has no history of allergy or sensitivity to products containing latex&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>November 8, 2006</last_update_submitted>
  <last_update_submitted_qc>November 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2006</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

